Teva's US exclusive-dealing claims survive Corcept's move to dismiss
MLex Summary: Teva's antitrust claims that Corcept Therapeutics developed and implemented illegal exclusive-dealing arrangements can advance, a California federal judge ruled. In an order partially denying Corcept and Optime Care's motion...To view the full article, register now.
Already a subscriber? Click here to view full article